Drugs / BMN053
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01957059 | Jun 2013 → Aug 2016 | Duchenne muscular dystrophy | BioMarin Pharmaceutical | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMN 053 | “A Phase I/II, open-label, dose escalating with 48-week treatment study to assess the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of BMN 053...” NCT01957059 ↗1“The purpose of the study is to see whether BMN053 is safe and effective to use as medication for Duchenne muscular dystrophy (DMD) patients with a mutation around location 53...” NCT01957059 ↗ |
| Known as | PRO053 | “A Phase I/II, open-label, dose escalating with 48-week treatment study to assess the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of BMN 053...” NCT01957059 ↗ |
| Route | Intravenous | “All doses of BMN053 will be administered as IV infusions.” NCT01957059 ↗ |